INTEGRA LIFESCIENCES HOLDINGS CORP Net Change in Cash
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Net Change in Cash of -$20.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-07-29
- INTEGRA LIFESCIENCES HOLDINGS CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $1.76M.
- INTEGRA LIFESCIENCES HOLDINGS CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$7.27M, a 102.30% decline year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $315.50M.
- INTEGRA LIFESCIENCES HOLDINGS CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$149.29M.
- INTEGRA LIFESCIENCES HOLDINGS CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$11.33M.
- INTEGRA LIFESCIENCES HOLDINGS CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$30.03M.
- INTEGRA LIFESCIENCES HOLDINGS CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$180.26M.
- INTEGRA LIFESCIENCES HOLDINGS CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$56.79M, a 231.20% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.63M 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | $1.76M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | -$11.33M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$14.19M 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | -$28.46M 10-Q · filed 2026-07-29 | |||
| 2025-03-31 | -$7.27M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | -$30.03M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | -$61.24M 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | -$61.17M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $315.50M 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | -$180.26M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$182.93M 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | -$147.47M 10-Q · filed 2024-07-29 | |||
| 2023-03-31 | -$149.29M 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$56.79M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | -$1.51M 10-Q · filed 2023-10-25 | |||
| 2022-06-30 | -$66.30M 10-Q · filed 2023-07-27 | |||
| 2022-03-31 | -$106.36M 10-Q · filed 2023-04-26 | |||
| 2021-12-31 | $43.28M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $65.00K 10-Q · filed 2022-10-26 | |||
| 2021-06-30 | -$72.75M 10-Q · filed 2022-07-27 | |||
| 2021-03-31 | -$61.19M 10-Q · filed 2022-04-27 | |||
| 2020-12-31 | $271.25M 10-K · filed 2023-02-22 | |||
| 2020-09-30 | $197.37M 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $162.07M 10-Q · filed 2021-07-29 | |||
| 2020-03-31 | $158.80M 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | $60.07M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $69.14M 10-Q · filed 2020-10-29 | |||
| 2019-06-30 | $37.25M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $18.19M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$36.10M 10-K · filed 2021-02-23 | |||
| 2018-09-30 | $31.06M 10-Q · filed 2019-10-25 | |||
| 2018-06-30 | $8.84M 10-Q · filed 2019-07-25 | |||
| 2018-03-31 | $14.46M 10-Q · filed 2019-04-29 | |||
| 2017-12-31 | $72.88M 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |